Category: Precision Medicine
Exhibitor: YD BIO LIMITED
Booth No: N/A
Characteristic
OkaiDx is YD Bio's cancer diagnostics brand, built on exclusive licenses from EG BioMed covering DNA methylation technology for pancreatic cancer (U.S. Patent No. 12,258,636 B2) and breast cancer (U.S. Patent No. 12,203,140 B2). Using only 8 mL of blood, the platform detects abnormal methylation in circulating tumor DNA (ctDNA) for non-invasive cancer screening. The pancreatic cancer early detection test is available as an LDT across 44 U.S. states through a CAP-accredited, CLIA-certified laboratory; the breast cancer monitoring test is currently available for research use, with findings presented at the ASCO Annual Meeting.
Other Products
Products you may be interested in
Highest Rated Products